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Introduction
Dental Fear and Anxiety (DFA), have a prevalence from 5 to 20% 
in children and adolescents [1]. DFA in children and adolescents 
has multifaceted manifestations, impacts and origins. Children and 
adolescents with DFA are often uncooperative during dental visits, 
thus rendering treatment difficult or impossible [ [2]. Such behaviour 
compromises the treatment outcome, creates occupational stress among 
dentist staff, and is often a cause of discord between dental professionals 
Abstract
Aim: Fear and anxiety are the principal obstacles for dental treatment 
in children and can turn into dental phobia, leading to patients avoiding 
dental treatment. Melatonin, an endogenous indolamines produced 
and secreted by the pineal gland, is involved in many physiological 
functions such as regulation of circadian rhythm as well as possessing 
antioxidant, oncostatic, anti-inflammatory and anticonvulsant activity; 
it may be administered orally or sublingually, without any evidence of 
substantial side effects. After oral administration, melatonin undergoes 
first-pass effect, reaches the plasma peak after about 60 min and blood 
levels decrease in about 4 h. 
Study Design: This is a retrospective case-control age and sex 
matched study. We collected data about first visit and treatment of 50 
patients admitted to the Dental Clinic and to the Private Center of the 
investigators. 
Methods: According to literature, 25 children received 0.5 mg/
kg Melatonin 60’ before being subjected to first visit and pedodontic 
treatment. No preventive treatment was given to 25 children. We 
compared the success of treatment and the pain experienced by the 
child assessed by FLACC behavioural pain scale. 
Results: Both groups included 25 patients (15 male), mean age 
7.6 yrs in Group A, 7.1 yrs in Group B. Melatonin treatment was well 
tolerated by 100% of children. According to FLACC scale categories, 
42% of all children presented relaxed and comfortable or mild 
discomfort (FLACC scale 0-3), 42% moderate pain (FLACC scale 4-6), 
and 16% severe discomfort or pain or both (FLACC scale 7-10). 
Statistics: Operators found greater compliance by children receiving 
melatonin with 96 % successful treatment versus 68% (p 0.012). We 
found 60% of children receiving melatonin experienced relaxed and 
comfortable o mild discomfort versus 40% in Group B (p 0.001). 
Conclusions: Although a larger population study is needed, the 
anxiolytic and analgesic properties of melatonin seem to offer new 
therapeutic opportunity in the pedodontic field.
and patients or their parents [3]. DFA acquired in childhood may 
persist to adulthood and is a significant predictor of avoidance of dental 
visits in adulthood [3]. This pinpoints childhood as a critical stage for 
preventing and intercepting DFA, thus helping people to protect their 
oral health in the long term.
Recently, Marseglia L. et al. suggested new potential uses of 
melatonin in pediatric patients for its analgesic, anxiolytic and 
anaesthetic effects [4]. This endogenous indolamines produced and 
secreted by the pineal gland, is involved in numerous physiological 
functions such as regulation of circadian rhythm, as well as having 
antioxidant, oncostatic, anti-inflammatory and anticonvulsant activity 
[5]. From a clinical standpoint, exogenous melatonin is mainly used for 
the treatment of sleep disorders, but given the hypnotic properties it 
has been suggested that it may be used at different stages of anesthesia 
procedures [4]. Numerous experimental studies promote further 
therapeutic possibilities: it has been shown that melatonin has a sedative 
and anticonvulsant action supporting GABAergic transmission at the 
central level  [6]. In addition, it has been characterized by an analgesic 
activity of melatonin, which is now used in adult patients in the treatment 
of chronic pathology [7]. From a strictly pharmacokinetic point of view, 
exogenous melatonin may be administered orally or sublingually, both 
in adults and children, without any evidence of substantial side effects 
[8]. After oral administration, melatonin undergoes first-pass effect, 
reaches the plasma peak after about 60 min and blood levels decrease 
in about 4 h [9].
Melatonin has its important clinical application in analgesia despite 
the biochemical mechanisms that have not been fully clarified; However, 
numerous experimental data have demonstrated the involvement of a 
series of endogenous substances and molecular targets [10]. For example, 
melatonin promotes the release of β-endorphins from the pituitary 
gland, favouring analgesia; naloxone is able to antagonize this effect as it 
prevents the binding of β-endorphins released with the opioid receptors, 
underlining its direct implication. The interactions of melatonin with 
membrane receptors, opioid 1-receptors, or Gamma-aminobutyric 
Acid-β (GABA-β) receptors, all of which are coupled to protein G, 
as well as having beneficial effects on pain perception, also result in 
anxiety. In addition, in view of the ability of melatonin to inhibit the 
production of nitric oxide, reduce the activation of the Nuclear Factor-
κB (NF-kB) transcription factor, the expression of cyclooxygenase 
(COX) and prostaglandin and to recruit polymorphonuclear cells 
at the inflammation site Suggested a possible use of melatonin in the 
treatment of pain associated with pulp inflammatory processes [11]. 
Animal models demonstrated the existence of a circadian rhythm in the 
perception of pain finely regulated by melatonin: in an experimental 
study, the higher plasma levels of melatonin achieved at night in 
rats were associated with a lower sensitivity to pain but also higher 
morphine sensitivity than observed during waking hours [12]. The 
anxiolytic activity of melatonin demonstrated by animal models is 
confirmed by clinical trials conducted on adult patients undergoing 
stress, such as surgery and subsequent hospitalization [13,14]. Exactly as 
observed in animals, in these conditions, plasma melatonin levels were 
very low and oral administration in these patients proved to be useful 
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in more than one aspect: It alleviated the state of preoperative anxiety, 
facilitated the induction of sleep, and improved post-operative pain 
control. Studies designed to investigate melatonin anaesthetic activity 
in adult patients have demonstrated the same pre-operative anxiolytic 
efficacy as midazolam (Gold standard) and furthermore, there was 
a lower incidence of postoperative excitement, sleep disturbance and 
delirium manifestations [15]. However, other studies have shown less 
efficacy of melatonin than midazolam [16]. The aim of the study was to 
evaluate the role which may be played by melatonin in the management 
of children in paediatric dentistry. 
Materials and Methods
This is a retrospective case-control age and sex matched study. 
Participants were recruited among children attending the Dental Clinic 
and the Private Centre of the investigators from January 1st through 
July 1st, 2017. Inclusion criteria for patients were: Caucasian, aged 
4-10, at their first pedodontic evaluation and without other diseases. 
We compared data collected during patient’s first visit to evaluate the 
anxiolytic and analgesic effects of melatonin in paediatric dentistry.
GROUP A included 25 children who, according to literature [17], 
received Melatonin 0.5 mg/kg orally 60’ before being subjected to first 
visit and pedodontic treatment and GROUP B included 25 children age 
and sex matched with patients of GROUP A who didn’t received any 
preventive treatment. We collected data recorded by the operator at the 
end of each patient’s visit, comparing success of treatment, anxiety and 
pain experienced by the child assessed by Face, Legs, Activity, Cry and 
Consolability (FLACC) behavioural pain scale according to literature 
[18].
Therefore, we identified 3 categories according to FLACC scale: 
relaxed and comfortable or mild discomfort (FLACC scale 0-3); 
moderate pain (FLACC scale 4-6); severe discomfort or pain or both 
(FLACC scale 7-10).
Statistical Analysis
Descriptive statistics were performed. Qualitative variables were 
summarised in terms of absolute frequencies or percentages, and 
quantitative variables were summarised in terms of mean ± standard 
deviation. A comparison of frequencies was performed by the Chi-
square test or by the Fisher Exact test (in case of expected frequencies 
less than 5). All tests were two-sided and p ≤ 0.05 was considered as 
statistically significant. The software used for statistical analyses was 
Excel 2010 (Microsoft Corp. Redmond, WA, USA). 
Results
Data of patients in the two groups are summarized in Table 1. 
Group A included 25 patients (11 male, mean age 6.7 yrs ± 1.87; min 4.1 
yrs, max 9.8 yrs), all pre-treated by administration of melatonin. Group 
B included 25 patients (11 male, mean age 7.5 years ± 1.89; min 4.0 
yrs, max 9.7 yrs). Melatonin treatment was well tolerated by 100% of 
children. Physicians found greater collaboration with children of Group 
A: 96% successful treatment of the group receiving melatonin versus 
68% in the group B (p 0.012). According to FLACC scale categories, 42% 
of all children presented relaxed and comfortable or mild discomfort 
(FLACC scale 0-3), 42% moderate pain (FLACC scale 4-6), and 16% 
severe discomfort or pain or both (FLACC scale 7-10). Moreover, in 
Group A, 60% of patients presented relaxed and comfortable or mild 
discomfort (FLACC scale 0-3), versus 24% in Group B; 32% of children 
of Group A showed moderate pain (FLACC scale 4-6) versus 52% in 
Group B; then, severe discomfort or pain or both (FLACC scale 7-10) 
was experienced by 8% of patients of Group A, versus 24% in Group B 
(p 0.025).
Finally we compared two categories of FLACC scale: relaxed and 
confortable o mild discomfort (FLACC scale 0-3), versus moderate 
pain and severe discomfort or pain or both (FLACC scale 4-10). We 
found 60% of children receiving melatonin experienced relaxed and 
comfortable o mild discomfort versus 40% in Group B (p 0.001). 
Conclusions
The deep impacts of DFA on children and adolescents reinforce 
the idea that managing fear and anxiety should be a starting point in 
patient management otherwise it can turn to dental phobia, leading 
to patients avoiding dental treatment. Midazolam was introduced 
as a premedication for children since 1980s. Although it can be 
administered via multiple routes, it is currently preferred as oral 
medication because of its rapid absorption and low incidence of nausea 
vs. other benzodiazepines [19]. However, midazolam has several side 
effects, including paradoxical reactions, interactions with opioids, 
variable bioavailability and elimination half-life, excessive sedation, 
disorientation, impaired psychomotor performance and amnesia [20]. 
In light of these findings, Naguib M in 1999 proposed melatonin as 
alternative to midazolam as a premedicant in procedures preceding 
anaesthesia induction [21]. Samarkandi et al. reported that 0.25 and 0.5 
mg/kg melatonin was not only as effective as midazolam in alleviating 
preoperative anxiety in children but also associated with a tendency 
toward faster recovery, lower incidence of excitement postoperatively 
[22]. But according to Isik B. et al., in terms of effectiveness of the 
sedation in melatonin groups were not similar to that of these research 
[17].
Our data showed better compliance in children receiving melatonin 
and higher rate of successful treatment. Interestly, in our experience 
melatonin significantly reduced FLACC score both reducing pain than 
anxiety. Then, although studies about use of melatonin on children have 
provided conflicting results, our experience shows the analgesic and 
hypnotic properties of melatonin offer new therapeutic possibilities in 
the pediatric dentistry.
All patients 
(N=50) N (%)
Patients Group A 
(N=25) N (%)
Patients Group B 
(N=25) N (%) P
Gender: Males 22 (44.0) 11 (44.0) 11 (56.0) 1§
Females 28 (56.0) 14 (44.0) 14 (56.0)
successful treatment: yes 41 (82.0) 24 (96.0) 17 (68.0) 0.012#
No 9 (18.0) 4 (4.0) 8 (32.0)
scale FLACC: 0-3 (Relaxed and comfortable o mild discomfort) 21 (42.0) 15 (60.0) 6 (24.0) 0.025§
4-6 (Moderate pain) 21 (42.0) 8 (32.0) 13 (52.0)
7-10 (Severe discomfort or pain or both) 8 (16.0) 2 (8.0) 6 (24.0)
scale FLACC: 0-3 (Relaxed and comfortable o mild discomfort) 21 (42.0) 15 (60.0) 6 (24.0) 0.001§
4-10 (Moderate pain, severe discomfort or pain or both) 29 (58.04) 10 (40.0) 19 (76.0)
§P refers to the Chi-square test; #P refers to the Fisher Exact
Table 1: Patients’ characteristics and relationships between successful treatment and scale FLACC and patient’s treatment.
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In light of its diverse origins, DFA could be better prevented and 
intercepted through coordinated efforts of pediatric dentists, dental 
auxiliaries, pediatric patients, and their parents. Thoughtful approaches 
before, during, and after the dental visit contribute in one way or 
another to a pleasant and productive dental experience. Successful 
DFA management not only paves the road to satisfactory clinical 
outcome and better oral health, but also builds confidence in pediatric 
patients and may help them regulate their emotions while facing other 
challenges in life. In our opinon, analgesic and hypnotic properties of 
melatonin seem to offer new therapeutic possibilities in the pedodontic 
field, however larger population study is needed.
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